Ravasio, R., M. Tiseo, L. Pradelli, M. Bellone, A. Gervasi, and M. Coffani. “Cost-Effectiveness Analysis of Alectinib Versus Crizotinib in First-Line Treatment of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer”. Global and Regional Health Technology Assessment, vol. 6, no. 1, June 2019, doi:10.33393/grhta.2019.462.